Drug Profile
AS 109
Alternative Names: PepscanLatest Information Update: 19 Jul 2012
Price :
$50
*
At a glance
- Originator Antisoma
- Class Peptides; Radiopharmaceutical diagnostics
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 11 Jan 2012 Discontinued - Clinical-Phase-Unknown for Breast cancer in Japan (unspecified route)
- 08 Nov 2002 AS 109 is available for licensing (www.antisoma.com)
- 19 Aug 2002 No development reported - Phase I/II for Breast cancer (diagnosis) in Japan (unspecified route)